secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001140361-26-016324
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for Grace Therapeutics' GTx-104 NDA; cites CMC and non-clinical issues
--------------------------------------------------------------------------------

- FDA CRL for GTx-104 (nimodipine IV) in aSAH; no additional clinical data requested.
- Cited leachables data, non-clinical toxicology, and manufacturing deficiencies at CMO.
- Company plans Type A meeting with FDA and intends to resubmit after resolving cited items.
- STRIVE-ON trial met primary endpoint; 19% reduction in hypotension vs. oral nimodipine.
- No deaths deemed drug-related; favorable functional outcomes and higher dose intensity observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126016324/0001140361-26-016324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126016324/ef20070593_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-016324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer